| Veronica L Boocher, RN | |
|
700 Liberty Ln, Dayton, OH 45449-2135 | |
| (937) 247-2400 | |
| Not Available |
| Full Name | Veronica L Boocher |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 700 Liberty Ln, Dayton, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013504406 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WA0400X | Registered Nurse - Addiction (substance Use Disorder) | 474632 (Ohio) | Secondary |
| 171M00000X | Case Manager/care Coordinator | RBT-22-207802 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Veronica L Boocher, RN 445 E Dublin Granville Rd, Worthington, OH 43085-3192 Ph: (614) 844-3800 | Veronica L Boocher, RN 700 Liberty Ln, Dayton, OH 45449-2135 Ph: (937) 247-2400 |
News Archive
Generex Biotechnology Corporation today announced the results of the Company's annual meeting of stockholders held on July 28, 2010.At the annual meeting of stockholders, the following current directors were elected to serve on the Board of Directors until the next annual meeting of stockholders: Anna Gluskin, Rose Perri, Brian McGee, John Barratt, and Nola Masterson. Stockholders also ratified the appointment of MSCM LLP as the Company's independent registered public accounting firm for the year ending July 31, 2011.
We commend Speaker Nancy Pelosi and the House leadership for their efforts that made this vote possible, and we commend members of the House of Representatives who stood up to insurance company interests and voted yes, for real reform.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
A droplet of clear liquid can bend light, acting as a lens. Now, by exploiting this well-known phenomenon, researchers have developed a new process to create inexpensive high quality lenses that will cost less than a penny apiece.
› Verified 8 days ago